SABCS: Debu Tripathy Discusses PI3 Kinase Inhibitors in Breast Cancer
December 12, 2014
Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.
Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving a PI3 kinase inhibitor showed interesting results.
While the clinical trial involving the investigational agent pictilisib with an aromatase inhibitor had only modest results, interest in this type of targeted therapy remains, particularly in different stages of the disease and in combination with other drugs.
